University of Oxford and OSI have both returned for a $95.4m series C round that also included GV and, through the conversion of a note, Eli Lilly.
Evox Therapeutics, a UK-based exosome drug spinout of University of Oxford, raised £69.2m ($95.4m) in a series C round yesterday featuring the institution and its patient capital fund Oxford Sciences Innovation (OSI).
Redmile Group led the round and was joined by GV, a corporate venturing arm of internet technology group Alphabet, OrbiMed, Invus, Panacea Healthcare Ventures, Borealis Ventures, Cowen Healthcare Investments and angel investors.
Eli Lilly participated in the series C round by converting a $10m note it…
